Carbimazole-induced agranulocytosis: does antineutrophil cytoplasmic antibody have a role?
Carbimazole is a drug that is widely used for hyperthyroid disorders, such as Graves' disease. Agranulocytosis is a rare idiosyncratic adverse reaction to the drug which is potentially fatal. This report describes a patient with a history of successfully treated pyoderma gangrenosum, who developed agranulocytosis 3 weeks after commencement of carbimazole for Graves' disease. It may give credence to the theory that implicates antineutrophil cytoplasmic antibodies in the pathogenesis of agranulocytosis induced by antithyroid drugs.
Department of Medicine, Austin Health, Melbourne, Victoria, Australia. garyyip2001@yahoo.com.au
G
G
Yip
E
E
Ekinci
S T
ST
Lee
G
G
Jerums
M
M
Grossmann
D000328:Adult; D000380:Agranulocytosis / Q000139:chemically induced / Q000175:diagnosis* / Q000276:immunology; D019268:Antibodies, Antineutrophil Cytoplasmic / Q000096:biosynthesis / Q000097:blood / Q000502:physiology*; D002231:Carbimazole / Q000009:adverse effects; D005260:Female; D006801:Humans
D019268:Antibodies, Antineutrophil Cytoplasmic; D002231:Carbimazole